Int J Neuropsychopharmacol. 2025 Aug 8:pyaf059. doi: 10.1093/ijnp/pyaf059. Online ahead of print.
ABSTRACT
BACKGROUND: Ulotaront is an experimental antipsychotic for schizophrenia, but its optimal dose is unclear. This study aimed to evaluate dose-response relationships for efficacy and safety in people with schizophrenia.
METHOD: A systematic review of four databases (until January 22, 2025; INPLASY202510091) identified randomized clinical trials assessing ulotaront. Outcomes included efficacy, measured by changes in the Positive and Negative Syndrome Scale (PANSS) total score (primary outcome), positive and negative subdomains, and the Clinical Global Impression Scale-Severity (CGI-S), and safety, assessed by all-cause dropout (co-primary outcome, dropout due to adverse event, serious, non-serious, and specific adverse events. We employed one-stage dose-response meta-analysis (random-effects model) calculating standardized mean differences (SMDs) and risk ratios (RRs) with 95% confidence intervals (CIs).
RESULTS: Analysis of three randomized clinical trials (n=1,144) indicated that the 100 mg dose of ulotaront provided the greatest improvement in PANSS total score (SMD = -0.23 [95% CI: -0.43, -0.02]), PANSS positive symptom score (-0.30 [-0.70, 0.10]), and PANSS negative symptom score (-0.28 [-0.48, -0.08]). However, CGI-S scores did not exhibit a clear dose-response relationship. Regarding safety, all-cause dropout (RR at 100mg =1.10 [95% CI: 0.57, 2.12]), adverse event-related dropout, serious, non-serious, and most specific adverse events showed no significant dose-response relationship. The risk of anxiety-related adverse events was significantly higher than placebo at 50 mg and 75 mg doses (RR at 75mg =2.06 [95% CI: 1.11, 3.80]).
CONCLUSION: Ulotaront 100 mg appears greatest efficacy with favorable safety for acute schizophrenia. However, effect sizes were small, and higher ulotaront doses should be tested.
PMID:40795331 | DOI:10.1093/ijnp/pyaf059
